|
Dr. Jacob brings to Glyconix over 28 years of medical and pharmaceutical industry experience. During 1997, Dr. Jacob founded InKine Pharmaceutical Company, Inc., a specialty pharmaceutical company that developed and commercialized gastrointestinal products including Visicol, a tablet alternative preparation for colonoscopy, and IBStat, a treatment for Irritable Bowel Syndrome. Dr. Jacob served as Chairman and CEO of InKine from 1997 until the company was acquired by Salix Pharmaceuticals in September 2005. In 1989, Dr. Jacob co-founded Magainin Pharmaceuticals and served as the company's Chief Operating Officer until 1996. From 1980 to 1989, Dr. Jacob served as Worldwide Vice President of SmithKline Beecham Corp. (now Glaxo- SmithKline). Dr. Jacob earned a Ph.D. in pharmacology from Temple University in 1975 and an M.D, from the Medical College of Pennsylvania (now Drexel University College of Medicine), Dr. Jacob currently serves on the Board of Directors for the Colon Cancer Alliance and the Board of Overseers for Temple University School of Medicine. In addition, Dr, Jacob is the founding Director of the Jacob Internet Fund, a public mutual fund, as well as MacroMed, private drug delivery company and Bradley Pharmaceuticals, Inc (NYSE: BDY). | 